<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="491">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04460534</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A01206-33</org_study_id>
    <nct_id>NCT04460534</nct_id>
  </id_info>
  <brief_title>Detection of COVID-19 (SARS-CoV-2) in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab)</brief_title>
  <acronym>COVISPERM</acronym>
  <official_title>Detection of SARS-CoV-2 in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GCS Ramsay Santé pour l'Enseignement et la Recherche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GCS Ramsay Santé pour l'Enseignement et la Recherche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to look for the presence of SARS-CoV-2 in the semen of
      patients diagnosed with COVID+ based on RT-PCR analysis of nasopharyngeal swabs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective monocentric, open-label, prospective study of male patients with
      CoV-2-SARS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a prospective monocentric, open-label, prospective study of male patients with CoV-2-SARS.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Testing for the presence of COVID-19 (SARS-CoV-2 virus) in the semen</measure>
    <time_frame>48 hours</time_frame>
    <description>The search for the SARS-CoV-2 virus in semen will be carried out by RT-PCR analysis with the RealStar kit developed by Altona Diagnostics. The extraction of the nucleic acid suitable for sperm uses the Pure MagNA technique (Diagnostics ROCHE). This is an extraction technique that has already been validated for HIV-type RNA viruses in semen.
The biological samples will be analysed either during the study or bio-banked and analysed at the end of the study. Only semen samples from patients detected positive for SARS-CoV-2 by RT-PCR on nasopharyngeal swab will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kinetics of SARS-CoV-2 virus presence in the semen</measure>
    <time_frame>1 month</time_frame>
    <description>Patients who have been found to carry the SARS-CoV-2 virus in their semen will be recalled after one month to re-test for the virus. In case of a positive re-test, a new search will be scheduled and so on until a negative result is found.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>COHORT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>diagnostic</intervention_name>
    <description>The principle of this study is to propose to patients in whom a COVID-19 infection is suspected and who are screened for the disease, the joint search for the virus in the semen.</description>
    <arm_group_label>COHORT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patient between the ages of 18 and 65 who has read and signed the consent form
             for participation in the study.

          -  Outpatient or inpatient without signs of respiratory severity, likely to be mobile

          -  Patient whose medical condition warrants screening for COVID-19 by nasopharyngeal swab

        Exclusion Criteria:

          -  Patient under protective custody, guardianship or trusteeship

          -  Patient not affiliated to the French social security system

          -  Inability to provide the subject with informed information and/or written informed
             consent: dementia, psychosis, consciousness disorders, non-French speaking patient
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Semen collection</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucie DELAROCHE, Pharm D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital privé de Parly II</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucie DELAROCHE, Pharm D</last_name>
    <phone>01 39 63 70 00</phone>
    <phone_ext>33</phone_ext>
    <email>luciedelaroche@yahoo.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pierre OGER, MD</last_name>
    <phone>01 39 63 70 00</phone>
    <phone_ext>33</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Privé de Parly II</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie DELAROCHE, Pharm D</last_name>
      <phone>01 39 63 70 00</phone>
      <phone_ext>33</phone_ext>
      <email>luciedelaroche@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Pierre OGER, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 2, 2020</study_first_submitted>
  <study_first_submitted_qc>July 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

